Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q1 FY25 Earnings Presentation
19 slides from Caplin Point Laboratories's earnings presentation, August 2024
Slide 1: Earnings Presentation Q1 FY25
EARNINGS PRESENTATION Q1 FY25 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* August 2024 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q1 FY25 Income Statement
Q1 FY25 Income Statement Revenue from Operations Gross Profit EBITDA 16% 25% 23% YoY YoY YoY 453 459 257 274 163 170 219 139 395 Q1 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q4 FY24 Q1 FY25 EBIT PAT Earnings Per Share 21% 20% YoY YoY 125 16.01 16.32 146 154 121 13.62 127 104 Q1 FY24 Q4 FY
Slide 4: Q1 FY25 Profit Margins
Q1 FY25 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 59.6% 35.7% 56.6% 34.5% 55.3% 34.0% Q1 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q4 FY24 Q1 FY25 EBIT Margins (%) PAT Margins (%) 32.3% 26.2% 31.2% 25.8% 31.1% 25.6% Q1 FY24 Q4 FY24 Q1 FY25 Q1 FY24 Q4 FY24 Q1 FY25 4
Slide 5: FY24 Income Statement
FY24 Income Statement Revenue from Operations Gross Profit EBITDA 16% 21% 24% YoY YoY YoY 1,694 618 970 497 1,467 804 FY23 FY24 FY23 FY24 FY23 FY24 EBIT PAT Profit Margins 25% 22% YoY YoY 54.8% 57.3% 565 461 452 377 35.1% 32.6% 29.7% 32.1% 24.8% 26.2% FY23 FY24 FY23 FY24 FY23 FY24 Gross Profit EBITD
Slide 6: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer Our company continues to be an outlier, whether its taki
Slide 7: Q1 FY25 Highlights (Emerging Markets)
Q1 FY25 Highlights (Emerging Markets) 01 02 03 04 Branded generic segment drives Caplin One Labs Oncology site Company’s LatAm business growth in profitability with Amaris Clinical, CRO wing of commences exports to LatAm, shows strong revenue and specialty products including Caplin Point, completes
Slide 8: Q1 FY25 Highlights (US and Regulated markets)
Q1 FY25 Highlights (US and Regulated markets) 01 02 03 04 Update on Caplin Steriles USA In-licensing of ANDAs and Company has received Caplin Steriles records Inc, company’s own label in the CMO for higher output approvals for 4 Ophthalmic impressive revenue growth US – 45 out of 50 state licenses t
Slide 9: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin projects equaling INR 600 Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris Markets Injectable unit launching own label in US Exchange China
Slide 10: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 85 2 Continuous capex investment of over INR 721 Cr over last 8 years towards enhanced manufacturing and R&D capabilities,
Slide 11: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY24 Operating Revenue (Emerging Markets) (Emerging Markets) 25% 18% 2% 75% 25% 55% 20% 80% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 12: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 12
Slide 13: Caplin Point Structure
Caplin Point Structure 100% Caplin Point Laboratories Subsidiary Caplin Steriles Ltd wholly Caplin Steriles USA Inc owned (BSE: 524742| NSE: CAPLIPOINT) (India) subsidiary (US) Manufacturing Units: Manufacturing Unit: Distribution: • CP I: Puducherry • CP IV: Gummidipoondi • Front-end trading arm fo
Slide 14: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 10 2 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3 3. Chengalpattu (CP III) 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chen
Slide 15: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline CP1, Caplin Plant I Suthukeny, Softgel Existing Markets Completed Q4 FY23 Puducherry CP4, Injectable Vials Line 5-Completed Caplin Steriles Gummidipoondi, and Pre-Filled Regulated Markets Line 6-Qualificati
Slide 16: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 17: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan D Sathya Narayanan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of experience in 35
Slide 18: P&L for the Q1 FY25 – Consolidated
P&L for the Q1 FY25 – Consolidated Value (INR Cr) Q1 FY25 Q1 FY24 YoY (%) Q4 FY24 QoQ (%) FY24 FY23 YoY (%) Revenue from Operation 458.96 395.32 16.1% 453.22 1.3% 1,694.10 1,466.73 15.5% Other Income 18.56 12.04 17.29 66.94 55.98 Total Revenue 477.52 407.36 17.2% 470.51 1.5% 1,761.04 1,522.72 15.7%
Slide 19: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram [email protected] CHURCHGATE PARTNERS Rajiv Pandya / Paresh Rohra [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited –
Caplin Point Laboratories — Q1 FY25 Earnings Presentation on 6ix